These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29428872)

  • 1. The win ratio approach did not alter study conclusions and may mitigate concerns regarding unequal composite end points in kidney transplant trials.
    Fergusson NA; Ramsay T; Chassé M; English SW; Knoll GA
    J Clin Epidemiol; 2018 Jun; 98():9-15. PubMed ID: 29428872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
    Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation--study design.
    Knoll GA; Cantarovitch M; Cole E; Gill J; Gourishankar S; Holland D; Kiberd B; Muirhead N; Prasad R; Tibbles LA; Treleaven D; Fergusson D
    Nephrol Dial Transplant; 2008 Jan; 23(1):354-8. PubMed ID: 17848393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
    Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
    Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
    Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
    Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
    Ruggenenti P; Perna A; Gherardi G; Garini G; Zoccali C; Salvadori M; Scolari F; Schena FP; Remuzzi G
    Lancet; 1999 Jul; 354(9176):359-64. PubMed ID: 10437863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.
    Ruggenenti P; Perna A; Gherardi G; Gaspari F; Benini R; Remuzzi G
    Lancet; 1998 Oct; 352(9136):1252-6. PubMed ID: 9788454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial.
    Abdalla S; Montez-Rath ME; Parfrey PS; Chertow GM
    Contemp Clin Trials; 2016 May; 48():119-24. PubMed ID: 27080930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
    Bilić M; Munjas-Samarin R; Ljubanović D; Horvatić I; Galesić K
    Coll Antropol; 2011 Dec; 35(4):1061-6. PubMed ID: 22397239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation.
    Arashi H; Sato T; Kobashigawa J; Luikart H; Kobayashi Y; Okada K; Sinha S; Honda Y; Yeung AC; Khush K; Fearon WF
    Am Heart J; 2020 Apr; 222():30-37. PubMed ID: 32007823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of long-term therapy with ramipril in high-risk women.
    Lonn E; Roccaforte R; Yi Q; Dagenais G; Sleight P; Bosch J; Suhan P; Micks M; Probstfield J; Bernstein V; Yusuf S;
    J Am Coll Cardiol; 2002 Aug; 40(4):693-702. PubMed ID: 12204499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramipril in the treatment of proteinuria in children after renal transplantation.
    Seeman T; Dusek J; Vondrák K; Janda J
    Pediatr Transplant; 2010 Mar; 14(2):283-7. PubMed ID: 19686445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.
    Li PK; Chow KM; Wong TY; Leung CB; Szeto CC
    Ann Intern Med; 2003 Jul; 139(2):105-12. PubMed ID: 12859160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
    Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
    Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.